Clinical trialsCompany release

Tyra reports 79% response rate for dabogratinib in FGFR3-altered low-grade bladder cancer

🇺🇸 Tyra Biosciences, Inc. (TYRA) · Tue 10 Nov 2026

Initial Phase 2 SURF302 data support a planned Phase 3 adjuvant study in 2027, while a roughly $400 million offering extends Tyra's cash runway to 2030.

Tyra Biosciences has reported third-quarter 2026 results alongside initial Phase 2 data for dabogratinib, its oral FGFR3 inhibitor, in non-muscle-invasive bladder cancer (NMIBC). The company announced the update on 10 November 2026.

In the SURF302 study, patients with FGFR3-altered, low-grade, intermediate-risk NMIBC who received 60 mg once daily showed an overall response rate of 79%. The summary available does not give patient numbers, durability or safety findings, so the strength of the result cannot yet be judged.

Tyra said it plans to engage health authorities on a Phase 3 adjuvant study of dabogratinib, which it expects to begin in 2027. Details of the design, comparator and endpoints were not included in the information available.

On the financial side, the company closed a public offering of about $400 million in September. It reported $700.5 million in cash and expects this to fund operations through 2030.

What it means for your team

  • Regulatory teams tracking FGFR3-targeted therapies should watch for Tyra's discussions with health authorities, which will shape the Phase 3 adjuvant programme planned for 2027.
  • The 79% response rate is an early Phase 2 figure; full data on patient numbers, durability and safety are needed before comparing it with other NMIBC options.
  • Market-access teams may note that a long cash runway, now projected to 2030, lowers near-term funding risk for the development programme.

Company's press release (SEC filing): Tyra Biosciences, Inc. ↗

Article written by VigiEye from the official source (Tyra Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →